- Home
- / AnHeart Therapeutics
AnHeart Therapeutics
AnHeart Therapeutics Summary
Company Summary
- Overview
- AnHeart Therapeutics (AHT, 葆元生物医药科技) is a company dedicated to the development of late clinical-stage oncology drugs. Its AB-106 product is a selective ROS1 and NTRK1-3 dual-target inhibitor.
- Type
- Private
- Status
- Active
- Founded
- 2018
- HQ
- New York, NY, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Lihua Zheng, Co-Founder & Chief Business Officer
Fan Frank Fan, Senior Vice President & Head of Clinical Development Strategy
Jun Li, Vice President of Pre-Clinical
